Abstract
A variety of different tumors can arise from any of the tissues present in the retroperitoneum, and they exhibit a wide range of pathologic types. Although computed tomography (CT) and magnetic resonance imaging (MRI) can demonstrate important characteristics of these tumors, diagnosis is often challenging for radiologists. The purpose of this pictorial essay is to review 18F-fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT) features of different kinds of benign and malignant retroperitoneal tumors in comparison with CT or MRI findings alone and to become familiar with the wide variety of imaging characteristics.
References
Lane RH, Stephens DH, Reiman HM. Primary retroperitoneal neoplasms: CT findings in 90 cases with clinical and pathologic correlation. AJR Am J Roentgenol. 1989;152:83–9.
Tateishi U, Terauchi T, Inoue T, Tobinai K. Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: PET/CT. Abdom Imaging. 2010;35:232–40.
Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50:21–30.
Conyers R, Young S, Thomas DM. Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2010. doi:10.1155/2011/483154.
Schwarzbach MH, Dimitrakopoulou-Strauss A, Mechtersheimer G, Hinz U, Willeke F, Cardona S, et al. Assessment of soft tissue lesions suspicious for liposarcoma by 18F-deoxy-glucose (FDG) positron emission tomography (PET). Anticancer Res. 2001;21:3609–14.
Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur J Nucl Med Mol Imaging. 2006;33:1290–5.
Kitajima K, Murakami K, Kaji Y, Sugimura K. Spectrum of FDG PET/CT of uterine tumors. AJR Am J Roentgenol. 2010;195:737–43.
Yamane T, Takaoka A, Kita M, Imai Y, Senda M. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma. Ann Nucl Med. 2012;26:478–84.
Tsujikawa T, Yoshida Y, Mori T, et al. Uterine tumors: pathophysiologic imaging with 16α-[18F]fluoro-17β-estradiol and 18F-fluorodeoxyglucose PET—initial experience. Radiology. 2008;248:599–605.
Ito K, Masuda-Miyata Y, Wada S, Morooka M, Yamasawa K, Hashimoto M, et al. F-18 FDG PET/CT imaging of bulky myxofibrosarcoma in chest wall. Clin Nucl Med. 2011;36:212–3.
Hwang SS, Park SY, Park YH. The CT and F-FDG PET/CT appearance of primary renal malignant fibrous histiocytoma. J Med Imaging Radiat Oncol. 2010;54:365–7.
Berrebi O, Steiner C. keller A, Rougemont AL, Ratib O. F-18 fluorodeoxyglucose (FDG) PET in the diagnosis of malignant transformation of fibrous dysplasia in the pelvic bones. Clin Nucl Med. 2008;33:469–71.
De Giorgi U, Pupi A, Fiorentini G, Rosti G, Marangolo M. FDG-PET in the management of germ cell tumor. Ann Oncol. 2005;16:90–4.
Otomi Y, Otsuka H, Morita N, Terazawa K, Furutani K, Harada M, et al. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. J Med Invest. 2010;57:270–4.
Park JW, Cho CH, Jeong D, Chae HD. Role of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric GIST: predicting malignant potential pre-operatively. J Gastric Cancer. 2011;11:173–9.
Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45:357–65.
Beaulieu S, Rubin B, Djang D, Conrad E, Turcotte E, Eary JF. Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning. AJR. 2004;182:971–4.
Hamada K, Tomita Y, Qiu Y, Tomoeda M, Ueda T, Tamai N, et al. 18F-FDG PET analysis of schwannoma: increase of SUVmax in the delayed scan is correlated with elevated VEGF/VPF expression in the tumors. Skeletal Radiol. 2009;38:261–6.
Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[Fulorine-18]fluoro-2-deoxy-d-glucose PET. Radiology. 1999;212:35–41.
Taieb D, Sebag F, Barlier A, Tessonnier L, Palazzo FF, Morange I, et al. 18F-FDG activity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med. 2009;50:711–7.
Miyake M, Tateishi U, Maeda T, Arai Y, Seki K, Hasegawa T, et al. A case of ganglioneuroma presenting abnormal FDG uptake. Ann Nucl Med. 2006;20:357–60.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kitajima, K., Kono, A., Konishi, J. et al. 18F-FDG-PET/CT findings of retroperitoneal tumors: a pictorial essay. Jpn J Radiol 31, 301–309 (2013). https://doi.org/10.1007/s11604-013-0192-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11604-013-0192-x